Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?
<p>Abstract</p> <p>Recently, the Food and Drug Administration placed a "black box" label on etanercept, and other tumor necrosis factor inhibitors used to treat childhood arthritis, warning of the risk of malignancies. The Food and Drug Administration made their decision...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-08-01
|
| Series: | Pediatric Rheumatology Online Journal |
| Online Access: | http://www.ped-rheum.com/content/8/1/23 |